| Two phase 3 trials of dupilumab versus placebo in atopic dermatitis EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ... New England Journal of Medicine 375 (24), 2335-2348, 2016 | 1950 | 2016 |
| Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). H Bocquet, M Bagot, JC Roujeau Seminars in cutaneous medicine and surgery 15 (4), 250-257, 1996 | 1302 | 1996 |
| Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United … EA Olsen, S Whittaker, YH Kim, M Duvic, HM Prince, SR Lessin, GS Wood, ... Journal of Clinical Oncology 29 (18), 2598-2607, 2011 | 708 | 2011 |
| Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ... The lancet oncology 19 (9), 1192-1204, 2018 | 607 | 2018 |
| Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ... The Lancet 390 (10094), 555-566, 2017 | 592 | 2017 |
| European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome–Update 2017 F Trautinger, J Eder, C Assaf, M Bagot, A Cozzio, R Dummer, R Gniadecki, ... European journal of cancer 77, 57-74, 2017 | 574 | 2017 |
| Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells A Nassif, A Bensussan, L Boumsell, A Deniaud, H Moslehi, P Wolkenstein, ... Journal of allergy and clinical immunology 114 (5), 1209-1215, 2004 | 520 | 2004 |
| European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell … NJ Senff, EM Noordijk, YH Kim, M Bagot, E Berti, L Cerroni, R Dummer, ... Blood, The Journal of the American Society of Hematology 112 (5), 1600-1609, 2008 | 510 | 2008 |
| EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary … W Kempf, K Pfaltz, MH Vermeer, A Cozzio, PL Ortiz-Romero, M Bagot, ... Blood, The Journal of the American Society of Hematology 118 (15), 4024-4035, 2011 | 503 | 2011 |
| Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and … JJ Scarisbrick, HM Prince, MH Vermeer, P Quaglino, S Horwitz, P Porcu, ... Journal of Clinical Oncology 33 (32), 3766-3773, 2015 | 459 | 2015 |
| Increasing comorbidities suggest that atopic dermatitis is a systemic disorder PM Brunner, JI Silverberg, E Guttman-Yassky, AS Paller, K Kabashima, ... Journal of Investigative Dermatology 137 (1), 18-25, 2017 | 432 | 2017 |
| Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis A Nassif, A Bensussan, N Bachot, M Bagot, L Boumsell, JC Roujeau, ... Journal of Investigative Dermatology 118 (4), 728-733, 2002 | 387 | 2002 |
| Vascular skin symptoms in COVID‐19: a French observational study JD Bouaziz, TA Duong, M Jachiet, C Velter, P Lestang, C Cassius, ... Journal of the European academy of dermatology and venereology 34 (9), e451, 2020 | 381 | 2020 |
| Blastic NK-Cell Lymphomas (Agranular CD4+ CD56+ Hematodermic Neoplasms) A Review T Petrella, M Bagot, R Willemze, M Beylot-Barry, B Vergier, M Delaunay, ... American journal of clinical pathology 123 (5), 662-675, 2005 | 378 | 2005 |
| Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases B Vergier, A de Muret, M Beylot-Barry, L Vaillant, D Ekouevi, G Chene, ... Blood, The Journal of the American Society of Hematology 95 (7), 2212-2218, 2000 | 349 | 2000 |
| What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature E Puzenat, V Bronsard, S Prey, PA Gourraud, S Aractingi, M Bagot, ... Journal of the European Academy of Dermatology and Venereology 24, 10-16, 2010 | 335 | 2010 |
| Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases F Grange, M Beylot-Barry, P Courville, E Maubec, M Bagot, B Vergier, ... Archives of dermatology 143 (9), 1144-1150, 2007 | 333 | 2007 |
| Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis L Valeyrie‐Allanore, P Wolkenstein, L Brochard, N Ortonne, B Maître, ... British Journal of Dermatology 163 (4), 847-853, 2010 | 318 | 2010 |
| Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study F Grange, MW Bekkenk, J Wechsler, C Meijer, L Cerroni, M Bernengo, ... Journal of clinical oncology 19 (16), 3602-3610, 2001 | 318 | 2001 |
| IL‐10 produced by activated human B cells regulates CD4+ T‐cell activation in vitro JD Bouaziz, S Calbo, M Maho‐Vaillant, A Saussine, M Bagot, ... European journal of immunology 40 (10), 2686-2691, 2010 | 314 | 2010 |
